Pardes up as COVID pill shows promise in early trial

Pardes Biosciences

14/02/2022 15:44

** Shares of COVID-19 antiviral pill developer Pardes
Biosciences  PRDS.O  up 2.8% to $12.55
    ** Co says interim data from ongoing early-stage trial of
its oral COVID-19 antiviral drug candidate, PBI-0451, shows that
it has potential to provide potent antiviral activity against
SARS-CoV-2 and emerging variants  urn:newsml:reuters.com:*:nL4N2UP2ZT
    ** Treatment was well tolerated with all treatment emergent
adverse events reported through Jan. 31, 2022 assessed as mild
in severity and resolved without intervention
    ** Co expects to begin mid-to-late stage study by mid 2022
    ** Pardes Biosciences went public through business
combination with a special purpose acquisition company, FS
Development Corp II, in December

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))